Svasti Haricharan

Dr. Svasti Haricharan


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2018 in Oncotarget
Verified
Journal Article
Open access
MAMeenakshi Anurag
Meenakshi Anurag
MEMatthew J. Ellis
Matthew J. Ellis
SHSvasti Haricharan
Svasti Haricharan

18 May 2020 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
AGAlexandra Garancher
Alexandra Garancher
HSHiromichi Suzuki
Hiromichi Suzuki
SHSvasti Haricharan
Svasti Haricharan
LCLianne Q. Chau
Lianne Q. Chau
MMMeher Beigi Masihi
Meher Beigi Masihi
RWRobert J. Wechsler-Reya
Robert J. Wechsler-Reya

28 July 2021 in Endocrinology
Verified
Journal Article
Open access
PDF file
AMAloran Mazumder
Aloran Mazumder
SSStephen Shiao
Stephen Shiao
SHSvasti Haricharan
Svasti Haricharan
The lethality of estrogen receptor alpha positive (ER+) breast cancer, which is often considered to have better prognosis than other subtypes, is defined by resistance to the standard of care endocrine treatment. Relapse and metastasis are inevitable in almost every patient whose cancer is resistant to endocrine treatment. Therefore, understanding the underlying causes of treatment resistance remains an important biological and clinical focus of research in this area. Growth factor receptor pathway activation, specifically HER2 activation, has been identified as 1 mechanism of endocrine treatment resistance across a range of experimental model systems. However, clinical trials conducted to test whether targeting HER2 benefits patients with endocrine treatment–resistant ER+ breast cancer have consistently and disappointingly shown mixed results. One reason for the failure of these clinical trials could be the complexity of crosstalk between ER, HER2, and other growth factor receptors and the fluidity of HER2 activation in these cells, which makes it challenging to identify stratifiers for this targeted intervention. In the absence of stratifiers that can be assayed at diagnosis to allow prospective tailoring of HER2 inhibition to the right patients, clinical trials will continue to disappoint. To understand stratifiers, it is important that the field invests in key understudied areas of research including characterization of the tumor secretome and receptor activation in response to endocrine treatment, and mapping the ER–HER2 growth factor network in the normal and developing mammary gland. Understanding these mechanisms further is critical to improving outcomes for the hard-to-treat endocrine treatment–resistant ER+ breast cancer cohort.

19 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
NPNindo B. Punturi
Nindo B. Punturi
SSSinem Seker
Sinem Seker
VDVaishnavi Devarakonda
Vaishnavi Devarakonda
AMAloran Mazumder
Aloran Mazumder
RKRashi Kalra
Rashi Kalra
SHSvasti Haricharan
Svasti Haricharan
Resistance to endocrine treatment occurs in ~30% of ER+ breast cancer patients resulting in ~40,000 deaths/year in the USA. Preclinical studies strongly implicate activation of growth factor receptor, HER2 in endocrine treatment resistance. However, clinical trials of pan-HER inhibitors in ER+/HER2− patients have disappointed, likely due to a lack of predictive biomarkers. Here we demonstrate that loss of mismatch repair activates HER2 after endocrine treatment in ER+/HER2− breast cancer cells by protecting HER2 from protein trafficking. Additionally, HER2 activation is indispensable for endocrine treatment resistance in MutL- cells. Consequently, inhibiting HER2 restores sensitivity to endocrine treatment. Patient data from multiple clinical datasets supports an association between MutL loss, HER2 upregulation, and sensitivity to HER inhibitors in ER+/HER2− patients. These results provide strong rationale for MutL loss as a first-in-class predictive marker of sensitivity to combinatorial treatment with endocrine intervention and HER inhibitors in endocrine treatment-resistant ER+/HER2− breast cancer patients.

1 January 2022 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
AMAloran Mazumder
Aloran Mazumder
AJAthena Jimenez
Athena Jimenez
RERachel E. Ellsworth
Rachel E. Ellsworth
SFStephen J. Freedland
Stephen J. Freedland
SGSophia George
Sophia George
SHSvasti Haricharan
Svasti Haricharan
Background: Estrogen receptor positive (ER+) breast cancer is one of the most commonly diagnosed malignancies in women irrespective of their race or ethnicity. While Black women with ER+ breast cancer are 42% more likely to die of their disease than White women, molecular mechanisms underlying this disparate outcome are understudied. Recent studies identify DNA damage repair (DDR) genes as a new class of endocrine therapy resistance driver that contributes to poor survival among ER+ breast cancer patients. Here, we systematically analyze DDR regulation in the tumors and normal breast of Black women and its impact on survival outcome. Method: Mutation and up/downregulation of 104 DDR genes in breast tumor and normal samples from Black patients relative to White counterparts was assessed. For DDR genes that were differently regulated in the tumor samples from Black women in multiple datasets associations with survival outcome were tested. Results: Overall, Black patient tumors upregulate or downregulate RNA levels of a wide array of single strand break repair (SSBR) genes relative to their white counterparts and uniformly upregulate double strand break repair (DSBR) genes. This DSBR upregulation was also detectable in samples of normal breast tissue from Black women. Eight candidate DDR genes were reproducibly differently regulated in tumors from Black women and associated with poor survival. A unique DDR signature comprised of simultaneous upregulation of homologous recombination gene expression and downregulation of SSBR genes was enriched in Black patients. This signature associated with cell cycle dysregulation ( p < 0.001), a hallmark of endocrine therapy resistance, and concordantly, with significantly worse survival outcomes in all datasets analyzed (hazard ratio of 9.5, p < 0.001). Conclusion: These results constitute the first systematic analysis of DDR regulation in Black women and provide strong rationale for refining biomarker profiles to ensure precision medicine for underserved populations.

30 June 2023 in Science Advances
Verified
Journal Article
Open access
EOElena Oropeza
Elena Oropeza
SSSinem Seker
Sinem Seker
SCSabrina Carrel
Sabrina Carrel
AMAloran Mazumder
Aloran Mazumder
DLDaniel Lozano
Daniel Lozano
SHSvasti Haricharan
Svasti Haricharan
Cell cycle dysregulation is prerequisite for cancer formation. However, it is unknown whether the mode of dysregulation affects disease characteristics. Here, we conduct comprehensive analyses of cell cycle checkpoint dysregulation using patient data and experimental investigations. We find that ATM mutation predisposes the diagnosis of primary estrogen receptor (ER) + /human epidermal growth factor (HER)2 − cancer in older women. Conversely, CHK2 dysregulation induces formation of metastatic, premenopausal ER + /HER2 − breast cancer ( P = 0.001) that is treatment-resistant (HR = 6.15, P = 0.01). Lastly, while mutations in ATR alone are rare, ATR / TP53 co-mutation is 12-fold enriched over expected in ER + /HER2 − disease ( P = 0.002) and associates with metastatic progression (HR = 2.01, P = 0.006). Concordantly, ATR dysregulation induces metastatic phenotypes in TP53 mutant, not wild-type, cells. Overall, we identify mode of cell cycle dysregulation as a distinct event that determines subtype, metastatic potential, and treatment responsiveness, providing rationale for reconsidering diagnostic classification through the lens of the mode of cell cycle dysregulation. .